Who owns MAZE?
Institutional ownership of Maze Therapeutics Inc. from Form 13F, Q2 2026
162 institutional managers reported holding Maze Therapeutics Inc. (MAZE) in Form 13F filings for Q2 2026, with 58,534,516 shares worth $1.7B. The largest reported holder was Frazier Life Sciences Management, L.P. Managers that filed both quarters added a net 6,310,027 shares (+12.9%). 37 opened new positions and 39 sold out.
- Funds holding
- 162
- Value held
- $1.7B
- New / sold out
- 37 / 39
- Net shares, same filers
- +12.9%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of MAZE
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | $150M | 8.6% | 5,032,915 | Added |
| TRV GP IV, LLC | $134M | 7.6% | 4,473,958 | Unchanged |
| ARCH Venture Management, LLC | $123M | 7.0% | 4,120,053 | Unchanged |
| Deep Track Capital, LP | $111M | 6.4% | 3,732,569 | Added |
| BlackRock, Inc. | $105M | 6.0% | 3,502,841 | Added |
| Jupiter Topco LLC | $102M | 5.8% | 3,408,045 | First report |
| T. Rowe Price Investment Management, Inc. | $77.7M | 4.4% | 2,603,682 | New |
| Logos Global Management LP | $57.7M | 3.3% | 1,935,000 | Added |
| Vanguard Capital Management LLC | $53.1M | 3.0% | 1,778,222 | Added |
| a16z Capital Management, L.L.C. | $50.8M | 2.9% | 1,702,225 | Unchanged |
| Venrock Adviser, LLC | $47.8M | 2.7% | 1,602,034 | Unchanged |
| Alphabet Inc. | $41.4M | 2.4% | 1,388,583 | Unchanged |
| Braidwell LP | $34.0M | 1.9% | 1,140,040 | New |
| Farallon Capital Management, L.l.c. | $33.1M | 1.9% | 1,107,814 | Added |
| FMR LLC | $31.5M | 1.8% | 1,056,959 | Added |
| General Catalyst Group Management, LLC | $30.9M | 1.8% | 1,035,910 | Unchanged |
| State Street Corp | $29.8M | 1.7% | 997,533 | Added |
| Driehaus Capital Management LLC | $28.5M | 1.6% | 954,886 | Added |
| TRV GP V, LLC | $28.4M | 1.6% | 950,800 | Unchanged |
| JPMorgan Chase & Co | $28.0M | 1.6% | 964,011 | Added |
| Marshall Wace, LLP | $27.3M | 1.6% | 914,572 | Added |
| Geode Capital Management, LLC | $25.6M | 1.5% | 858,054 | Added |
| Citadel Advisors LLC | $25.4M | 1.5% | 852,676 | Added |
| Casdin Capital, LLC | $25.2M | 1.4% | 843,857 | Added |
| ArrowMark Colorado Holdings LLC | $22.9M | 1.3% | 767,383 | Unchanged |
Share of 13F holdings is each fund's shares as a share of the 58,534,516 MAZE shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- T. Rowe Price Investment Management, Inc. New+$77.7M
- Braidwell LP New+$34.0M
- BlackRock, Inc. Added+$27.8M
- JPMorgan Chase & Co Added+$26.3M
- Farallon Capital Management, L.l.c. Added+$21.9M
- Logos Global Management LP Added+$20.9M
- Marshall Wace, LLP Added+$18.0M
- Frazier Life Sciences Management, L.P. Added+$13.9M
- State Street Corp Added+$10.8M
- Vanguard Capital Management LLC Added+$10.2M
Biggest sellers in Q2 2026
- Paradigm Biocapital Advisors LP Sold out-$81.9M
- Adage Capital Partners GP, L.l.c. Trimmed-$27.8M
- Cormorant Asset Management, LP Sold out-$22.4M
- Caligan Partners LP Sold out-$18.4M
- Balyasny Asset Management L.P. Trimmed-$13.2M
- Washington University Sold out-$8.4M
- Freestone Grove Partners LP Sold out-$7.0M
- Spruce Street Capital LP Sold out-$6.0M
- Foresite Capital Management IV, LLC Sold out-$4.7M
- Holocene Advisors, LP Sold out-$4.1M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $412M and sold $224M; 66 added and 37 trimmed.
Schedule 13D and 13G filings on MAZE
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-07-29BlackRock, Inc. SCHEDULE 13G filed by BlackRock Inc.Schedule 13G
- 2025-05-15ARCH Venture Fund X, L.P. SCHEDULE 13G filed by Maze Therapeutics Inc.Schedule 13G
- 2025-05-14Matrix Capital Management Company, LP SCHEDULE 13G filed by Maze Therapeutics Inc.Schedule 13G
- 2025-05-14JANUS HENDERSON GROUP PLC SCHEDULE 13G filed by Maze Therapeutics Inc.Schedule 13G
- 2025-05-09Third Rock Ventures IV, L.P. SCHEDULE 13G filed by Maze Therapeutics Inc.Schedule 13G
- 2025-02-07Foresite Capital Fund IV, L.P. SCHEDULE 13G filed by Maze Therapeutics Inc.Schedule 13G
- 2025-02-07Foresite Capital Fund IV, L.P. SCHEDULE 13G filed by Maze Therapeutics Inc.Schedule 13G
Questions about MAZE ownership
- Who owns MAZE stock?
- 162 institutional investment managers reported MAZE positions in their Form 13F filings for Q2 2026, holding 58,534,516 shares worth $1.7B in total. Frazier Life Sciences Management, L.P. reported the largest position.
- Are funds buying or selling MAZE?
- In Q2 2026, 37 managers opened new MAZE positions, 66 added, 37 trimmed and 39 sold out. Managers that filed in both quarters added a net 6,310,027 shares.
- How current is this MAZE institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to MAZE by CUSIP. Options are left out. MAZE news and filings · MAZE insider trades · Top funds